SVA [SINOVAC BIOTECH] 20-F: None None (Title of Class) Indicate the number

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2019-04-29, XBRL Interactive Financials
Original SEC Filing: Click here


Webplus: SVA/20190429/20-F/1/000.htm SEC Original: sva-20f_20181231.htm
None None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 71,139,402 common shares as of December 31, 2018 ☐ Yes ☒ No ☐ Yes ☒ No ☒ Yes ☐ No ☒ Yes ☐ No ☐ Large




Webplus: SVA/20190429/20-F/2_EX-4/000.htm SEC Original: sva-ex4_302.htm
Contract No.: Employment Contract (Fixed Term) Sinovac Biotech Co., Ltd. Party A: Party B: Signed on: Party A and Party B hereby enter into this contract and jointly comply with the terms contained herein upon consensus through negotiation based on the principles of equality and free will in accordance with the Labor Law of the People’s Republic of China, the




Webplus: SVA/20190429/20-F/3_EX-4/000.htm SEC Original: sva-ex4_303.htm
INDEMNIFICATION AGREEMENT Agreement Company Indemnitee This Indemnification Agreement (this “ RECITALS Board of Directors The Board of Directors of the Company (the “ AGREEMENT In consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows: DEFINITIONS A. The following terms shall have the meanings defined below: Expenses Indemnifiable Event Participant




Webplus: SVA/20190429/20-F/4_EX-8.1/000.htm SEC Original: sva-ex81_119.htm
List of Subsidiaries Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 1. Sinovac Biotech Co., Ltd., a PRC company 2. Sinovac Research & Development Co., Ltd., a PRC company 3. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 4. Sinovac Biomed Co., Ltd., a PRC company 5. EX-8.1 4 sva-ex81_119.htm EX-8.1




Webplus: SVA/20190429/20-F/5_EX-12.1/000.htm SEC Original: sva-ex121_118.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. 2. 3. 4. (a) (b) (c) (d) 5. (a) (b) Weidong Yin Chairman and Chief Executive Officer EX-12.1 5 sva-ex121_118.htm EX-12.1




Webplus: SVA/20190429/20-F/6_EX-12.2/000.htm SEC Original: sva-ex122_117.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. 2. 3. 4. (a) (b) (c) (d) 5. (a) (b) Nan Wang Chief Financial Officer EX-12.2 6 sva-ex122_117.htm EX-12.2




Webplus: SVA/20190429/20-F/7_EX-13.1/000.htm SEC Original: sva-ex131_116.htm
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) Weidong Yin Chairman and Chief Executive Officer EX-13.1 7 sva-ex131_116.htm EX-13.1




Webplus: SVA/20190429/20-F/8_EX-13.2/000.htm SEC Original: sva-ex132_114.htm
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) Nan Wang Chief Financial Officer EX-13.2 8 sva-ex132_114.htm EX-13.2




Webplus: SVA/20190429/20-F/9_EX-15.1/000.htm SEC Original: sva-ex151_115.htm
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT We consent to the incorporation by reference in the Registration Statement of Sinovac Biotech Ltd. on Form S-8 (FILE NO. 333-161827) and Form S-8 (FILE NO. 333-190980) of our report dated April 29, 2019, with respect to our audit of the consolidated financial statements of Sinovac Biotech Ltd. as of December 31, 2018 and




Webplus: SVA/20190429/20-F/10_EX-15.2/000.htm SEC Original: sva-ex152_193.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our report dated May 11, 2018 (except




Webplus: SVA/20190429/20-F/11_EX-15.3/000.htm SEC Original: sva-ex153_304.htm
April 29, 2019 100 F Street, N.E. Ladies and Gentlemen: Beijing, the People’s Republic of China EX-15.3 11 sva-ex153_304.htm EX-15.3



Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2019-04-29, XBRL Interactive FinancialsCIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200

Home Page Forums

By | 2019-04-30T04:16:00+00:00 April 29th, 2019|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar